Myovant Sciences Ltd.

2023 Q1 Form 10-Q Financial Statement

#000167908223000025 Filed on January 26, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4

Balance Sheet

Concept 2023 Q1 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $274.4M
YoY Change -48.0%
Cash & Equivalents $250.6M
Short-Term Investments $23.85M
Other Short-Term Assets $38.05M
YoY Change 82.96%
Inventory $30.08M
Prepaid Expenses
Receivables $41.02M
Other Receivables $2.997M
Total Short-Term Assets $386.6M
YoY Change -32.74%
LONG-TERM ASSETS
Property, Plant & Equipment $2.546M
YoY Change -13.75%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $7.291M
YoY Change -59.9%
Total Long-Term Assets $16.94M
YoY Change -42.67%
TOTAL ASSETS
Total Short-Term Assets $386.6M
Total Long-Term Assets $16.94M
Total Assets $403.5M
YoY Change -33.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $12.22M
YoY Change 0.72%
Accrued Expenses $90.04M
YoY Change 48.88%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $245.8M
YoY Change -8.65%
LONG-TERM LIABILITIES
Long-Term Debt $358.7M
YoY Change 0.0%
Other Long-Term Liabilities $1.717M
YoY Change 362.8%
Total Long-Term Liabilities $1.717M
YoY Change 362.8%
TOTAL LIABILITIES
Total Short-Term Liabilities $245.8M
Total Long-Term Liabilities $1.717M
Total Liabilities $961.7M
YoY Change -7.23%
SHAREHOLDERS EQUITY
Retained Earnings -$1.377B
YoY Change 15.41%
Common Stock $2.000K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$558.1M
YoY Change
Total Liabilities & Shareholders Equity $403.5M
YoY Change -33.22%

Cashflow Statement

Concept 2023 Q1 2022 Q4

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001679082
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--03-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37929
dei Entity Registrant Name
EntityRegistrantName
Myovant Sciences Ltd.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
D0
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1343578
dei Entity Address Address Line2
EntityAddressAddressLine2
7th Floor
dei Entity Address Address Line1
EntityAddressAddressLine1
50 Broadway
dei Entity Address City Or Town
EntityAddressCityOrTown
London
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
SW1H 0DB
dei Entity Address Country
EntityAddressCountry
GB
dei Country Region
CountryRegion
44
dei City Area Code
CityAreaCode
207
dei Local Phone Number
LocalPhoneNumber
400 3351
dei Security12b Title
Security12bTitle
Common Shares, $0.000017727 par value per share
dei Trading Symbol
TradingSymbol
MYOV
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
97235316 shares
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
250590000 usd
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
406704000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
41021000 usd
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
23296000 usd
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
23847000 usd
CY2022Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
27483000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
30084000 usd
CY2022Q1 us-gaap Inventory Net
InventoryNet
7584000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
38047000 usd
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
22498000 usd
CY2022Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
2997000 usd
CY2022Q1 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
580000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
386586000 usd
CY2022Q1 us-gaap Assets Current
AssetsCurrent
488145000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2546000 usd
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2944000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7098000 usd
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7961000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
7291000 usd
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
20961000 usd
CY2022Q4 us-gaap Assets
Assets
403521000 usd
CY2022Q1 us-gaap Assets
Assets
520011000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
12217000 usd
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
12250000 usd
CY2022Q4 myov Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
87333000 usd
CY2022Q1 myov Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
68594000 usd
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
117231000 usd
CY2022Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
100564000 usd
CY2022Q4 myov Accrued Liabilities Collaboration Agreement Current
AccruedLiabilitiesCollaborationAgreementCurrent
25768000 usd
CY2022Q1 myov Accrued Liabilities Collaboration Agreement Current
AccruedLiabilitiesCollaborationAgreementCurrent
32563000 usd
CY2022Q4 myov Collaborative Arrangement Liability Current
CollaborativeArrangementLiabilityCurrent
0 usd
CY2022Q1 myov Collaborative Arrangement Liability Current
CollaborativeArrangementLiabilityCurrent
33818000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2703000 usd
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2148000 usd
CY2022Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
501000 usd
CY2022Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
393000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
245753000 usd
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
250330000 usd
CY2022Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
350014000 usd
CY2022Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
375706000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5480000 usd
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7041000 usd
CY2022Q4 us-gaap Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
358700000 usd
CY2022Q1 us-gaap Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
358700000 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1717000 usd
CY2022Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1711000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
961664000 usd
CY2022Q1 us-gaap Liabilities
Liabilities
993488000 usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000017727
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000017727
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
564111242 shares
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
564111242 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
97028258 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
97028258 shares
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
94858446 shares
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
94858446 shares
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
2000 usd
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
2000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
835754000 usd
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
795935000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
-17285000 usd
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
-17285000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1376614000 usd
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1252129000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-558143000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-473477000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
403521000 usd
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
520011000 usd
CY2022Q4 us-gaap Revenues
Revenues
100229000 usd
CY2021Q4 us-gaap Revenues
Revenues
54440000 usd
us-gaap Revenues
Revenues
321545000 usd
us-gaap Revenues
Revenues
173405000 usd
CY2022Q4 myov Collaboration Expense
CollaborationExpense
26808000 usd
CY2021Q4 myov Collaboration Expense
CollaborationExpense
12086000 usd
myov Collaboration Expense
CollaborationExpense
67242000 usd
myov Collaboration Expense
CollaborationExpense
25912000 usd
CY2022Q4 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
86380000 usd
CY2021Q4 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
72125000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
249671000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
192118000 usd
CY2022Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31518000 usd
CY2021Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25726000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
82324000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
82886000 usd
CY2022Q4 myov Cost Of Goods And Services Sold And Operating Expenses
CostOfGoodsAndServicesSoldAndOperatingExpenses
152124000 usd
CY2021Q4 myov Cost Of Goods And Services Sold And Operating Expenses
CostOfGoodsAndServicesSoldAndOperatingExpenses
114180000 usd
myov Cost Of Goods And Services Sold And Operating Expenses
CostOfGoodsAndServicesSoldAndOperatingExpenses
416512000 usd
myov Cost Of Goods And Services Sold And Operating Expenses
CostOfGoodsAndServicesSoldAndOperatingExpenses
308813000 usd
CY2022Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-51895000 usd
CY2021Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-59740000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-94967000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-135408000 usd
CY2022Q4 us-gaap Interest Expense
InterestExpense
6118000 usd
CY2021Q4 us-gaap Interest Expense
InterestExpense
3479000 usd
us-gaap Interest Expense
InterestExpense
15131000 usd
us-gaap Interest Expense
InterestExpense
10478000 usd
CY2022Q4 us-gaap Investment Income Interest
InvestmentIncomeInterest
1591000 usd
CY2021Q4 us-gaap Investment Income Interest
InvestmentIncomeInterest
70000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
3095000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
248000 usd
CY2022Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-56422000 usd
CY2021Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-63149000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-107003000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-145638000 usd
CY2022Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1205000 usd
CY2021Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
296000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
17482000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1058000 usd
CY2022Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-57627000 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-57627000 usd
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-63445000 usd
CY2021Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-63445000 usd
us-gaap Net Income Loss
NetIncomeLoss
-124485000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-124485000 usd
us-gaap Net Income Loss
NetIncomeLoss
-146696000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-146696000 usd
CY2022Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.59
CY2022Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59
CY2021Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.68
CY2021Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.68
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.29
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.29
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.59
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.59
CY2022Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
96859108 shares
CY2022Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
96859108 shares
CY2021Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
93474985 shares
CY2021Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
93474985 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
96155644 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
96155644 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
92514657 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
92514657 shares
CY2022Q4 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
1362000 usd
us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
3766000 usd
CY2021Q4 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
1337000 usd
us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
3784000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-473477000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10001000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1191000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-21239000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-483524000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11901000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3993000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-45619000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-513249000 usd
CY2022Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11203000 usd
CY2022Q4 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1530000 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-57627000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-558143000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-353965000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11262000 usd
CY2021Q2 myov Adjustments To Additional Paid In Capital Share Based Compensation Liabilities Reclassified To Equity
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationLiabilitiesReclassifiedToEquity
1862000 usd
CY2021Q2 myov Adjustments To Additional Paid In Capital Share Based Compensation Expense Reclassified To Liabilities
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationExpenseReclassifiedToLiabilities
1377000 usd
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4252000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-61660000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-399626000 usd
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11863000 usd
CY2021Q3 myov Adjustments To Additional Paid In Capital Share Based Compensation Liabilities Reclassified To Equity
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationLiabilitiesReclassifiedToEquity
16297000 usd
CY2021Q3 myov Adjustments To Additional Paid In Capital Share Based Compensation Expense Reclassified To Liabilities
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationExpenseReclassifiedToLiabilities
915000 usd
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
11045000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-21591000 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-382927000 usd
CY2021Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7199000 usd
CY2021Q4 myov Adjustments To Additional Paid In Capital Share Based Compensation Liabilities Reclassified To Equity
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationLiabilitiesReclassifiedToEquity
2491000 usd
CY2021Q4 myov Adjustments To Additional Paid In Capital Share Based Compensation Expense Reclassified To Liabilities
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationExpenseReclassifiedToLiabilities
-554000 usd
CY2021Q4 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2565000 usd
CY2021Q4 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1280000 usd
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-63445000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-432283000 usd
us-gaap Net Income Loss
NetIncomeLoss
-124485000 usd
us-gaap Net Income Loss
NetIncomeLoss
-146696000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
32399000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
30324000 usd
us-gaap Depreciation
Depreciation
1012000 usd
us-gaap Depreciation
Depreciation
1062000 usd
myov Interest Expense Noncash
InterestExpenseNoncash
568000 usd
myov Interest Expense Noncash
InterestExpenseNoncash
1818000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1475000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1250000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-9000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
17725000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
15340000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
21794000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4126000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
15549000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7259000 usd
us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
2417000 usd
us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
550000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-9738000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
3641000 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-33000 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-5679000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
18739000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
13811000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-9025000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
3480000 usd
myov Increase Decrease In Accrued Liabilities Collaboration Agreement Current
IncreaseDecreaseInAccruedLiabilitiesCollaborationAgreementCurrent
-6795000 usd
myov Increase Decrease In Accrued Liabilities Collaboration Agreement Current
IncreaseDecreaseInAccruedLiabilitiesCollaborationAgreementCurrent
35773000 usd
myov Increase Decrease In Collaborative Arrangement Liability
IncreaseDecreaseInCollaborativeArrangementLiability
-34386000 usd
myov Increase Decrease In Collaborative Arrangement Liability
IncreaseDecreaseInCollaborativeArrangementLiability
-68654000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1618000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1326000 usd
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment
us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
108000 usd
us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
-152000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
6000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-2576000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-169782000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-168472000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
24864000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
118837000 usd
myov Proceeds From Maturities Prepayments And Calls Of Marketable Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfMarketableSecurities
28500000 usd
myov Proceeds From Maturities Prepayments And Calls Of Marketable Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfMarketableSecurities
59252000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
614000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
723000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3022000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-60308000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6714000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
17862000 usd
myov Proceeds From Capital Contribution Other
ProceedsFromCapitalContributionOther
0 usd
myov Proceeds From Capital Contribution Other
ProceedsFromCapitalContributionOther
1280000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6714000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19142000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-160046000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-209638000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
416804000 usd
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
677480000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
256758000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
467842000 usd
myov Noncash Increase Decrease In Deferred Compensation Share Based Arrangements Liability
NoncashIncreaseDecreaseInDeferredCompensationShareBasedArrangementsLiability
0 usd
myov Noncash Increase Decrease In Deferred Compensation Share Based Arrangements Liability
NoncashIncreaseDecreaseInDeferredCompensationShareBasedArrangementsLiability
1738000 usd
myov Noncash Reclassification Of Share Based Compensation Expense From Liabilities To Additional Paid In Capital
NoncashReclassificationOfShareBasedCompensationExpenseFromLiabilitiesToAdditionalPaidInCapital
0 usd
myov Noncash Reclassification Of Share Based Compensation Expense From Liabilities To Additional Paid In Capital
NoncashReclassificationOfShareBasedCompensationExpenseFromLiabilitiesToAdditionalPaidInCapital
20650000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
612000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13035034 shares
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the condensed consolidated financial statements and the accompanying notes, and the reported amounts of revenue and expenses during the reported periods. Actual results could differ materially from those estimates.</span></div>On an ongoing basis, the Company’s management evaluates its estimates, including those related to valuation of inventories, impairment testing for long-lived-assets, variables used in calculating the fair value of the Company’s equity awards, expected achievement of performance-based vesting criteria for equity awards, variable consideration and other relevant inputs impacting the gross and net revenue recognition, contingent liabilities, recoverability of deferred tax assets, determination of lease term, research and development (“R&amp;D”) expenses and accruals, and effective income tax rates. Management bases estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities as of the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period, that are not readily apparent from other sources. Estimates and assumptions are periodically reviewed considering changes in circumstances, facts, or experience. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. In addition, management’s assessment of the Company’s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows.
CY2022Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
274400000 usd
CY2022 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12130368 shares
CY2022Q4 us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
29307000 usd
CY2021Q4 us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
25172000 usd
us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
109025000 usd
us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
79853000 usd
CY2022Q4 us-gaap Revenues
Revenues
100229000 usd
CY2021Q4 us-gaap Revenues
Revenues
54440000 usd
us-gaap Revenues
Revenues
321545000 usd
us-gaap Revenues
Revenues
173405000 usd
CY2022Q1 myov Valuation Allowances And Reserves
ValuationAllowancesAndReserves
19876000 usd
myov Provision To Product Revenue Reserves Relating To Sales
ProvisionToProductRevenueReservesRelatingToSales
116684000 usd
myov Adjustments To Product Revenue Reserves
AdjustmentsToProductRevenueReserves
-129000 usd
myov Credits And Payments Made Applied Against Product Revenue Reserves
CreditsAndPaymentsMadeAppliedAgainstProductRevenueReserves
-99162000 usd
CY2022Q4 myov Valuation Allowances And Reserves
ValuationAllowancesAndReserves
37527000 usd
CY2022Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
37527000 usd
CY2022Q1 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
19876000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
250590000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
457742000 usd
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
6168000 usd
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
10100000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
256758000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
467842000 usd
CY2022Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
15597000 usd
CY2022Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
663000 usd
CY2022Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
6410000 usd
CY2022Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
3737000 usd
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
8077000 usd
CY2022Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
3184000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
30084000 usd
CY2022Q1 us-gaap Inventory Net
InventoryNet
7584000 usd
CY2022Q4 myov Accrued Sales Discounts Rebates And Allowances Current
AccruedSalesDiscountsRebatesAndAllowancesCurrent
36858000 usd
CY2022Q1 myov Accrued Sales Discounts Rebates And Allowances Current
AccruedSalesDiscountsRebatesAndAllowancesCurrent
19390000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
23516000 usd
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
26389000 usd
CY2022Q4 myov Accrued Researchand Development Current
AccruedResearchandDevelopmentCurrent
10244000 usd
CY2022Q1 myov Accrued Researchand Development Current
AccruedResearchandDevelopmentCurrent
6955000 usd
CY2022Q4 myov Accrued Commercial Expenses Current
AccruedCommercialExpensesCurrent
5287000 usd
CY2022Q1 myov Accrued Commercial Expenses Current
AccruedCommercialExpensesCurrent
7196000 usd
CY2022Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
4400000 usd
CY2022Q1 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
2470000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3288000 usd
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3309000 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3265000 usd
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1340000 usd
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
475000 usd
CY2022Q1 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
720000 usd
CY2022Q4 myov Deferred Net Product Revenue Current
DeferredNetProductRevenueCurrent
0 usd
CY2022Q1 myov Deferred Net Product Revenue Current
DeferredNetProductRevenueCurrent
825000 usd
CY2022Q4 myov Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
87333000 usd
CY2022Q1 myov Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
68594000 usd
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000017727
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000017727
CY2022Q4 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0214
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.1634
CY2021Q4 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0047
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0073
myov Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development Percent Of Relevant Spend
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentPercentOfRelevantSpend
0.90
CY2022Q4 myov Share Based Compensation Arrangement By Share Based Compensation Payment Award Number Of Plans
ShareBasedCompensationArrangementByShareBasedCompensationPaymentAwardNumberOfPlans
2 plan
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6130680 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
204808 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
826331 shares
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
106200000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
360368 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5148789 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5148789 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3830313 shares
CY2022Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10976000 usd
CY2021Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7047000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
32399000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
29864000 usd
CY2022Q4 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
347000 usd
CY2021Q4 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
184000 usd
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
1035000 usd
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
510000 usd
myov Share Based Payment Arrangement Settlement And Remeasurement Of Awards Cost
ShareBasedPaymentArrangementSettlementAndRemeasurementOfAwardsCost
3000000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M28D
CY2020Q4 us-gaap Proceeds From Collaborators
ProceedsFromCollaborators
146400000 usd
CY2022Q1 myov Collaborative Arrangement Liability
CollaborativeArrangementLiability
33818000 usd
us-gaap Proceeds From Collaborators
ProceedsFromCollaborators
0 usd
CY2022Q4 myov Collaborative Arrangement Liability
CollaborativeArrangementLiability
0 usd
CY2022Q1 myov Collaborative Arrangement Liability Current
CollaborativeArrangementLiabilityCurrent
33800000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-9000000 usd

Files In Submission

Name View Source Status
0001679082-23-000025-index-headers.html Edgar Link pending
0001679082-23-000025-index.html Edgar Link pending
0001679082-23-000025.txt Edgar Link pending
0001679082-23-000025-xbrl.zip Edgar Link pending
a12312022myovantex311.htm Edgar Link pending
a12312022myovantex312.htm Edgar Link pending
a12312022myovantex321.htm Edgar Link pending
a12312022myovantex322.htm Edgar Link pending
ex103-amendmenttoloanagr.htm Edgar Link pending
ex103-amendmenttoloanagr001.jpg Edgar Link pending
ex103-amendmenttoloanagr002.jpg Edgar Link pending
ex103-amendmenttoloanagr003.jpg Edgar Link pending
ex103-amendmenttoloanagr004.jpg Edgar Link pending
ex103-amendmenttoloanagr005.jpg Edgar Link pending
ex103-amendmenttoloanagr006.jpg Edgar Link pending
ex103-amendmenttoloanagr007.jpg Edgar Link pending
ex103-amendmenttoloanagr008.jpg Edgar Link pending
ex103-amendmenttoloanagr009.jpg Edgar Link pending
ex103-amendmenttoloanagr010.jpg Edgar Link pending
ex103-amendmenttoloanagr011.jpg Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
myov-20221231.htm Edgar Link pending
myov-20221231.xsd Edgar Link pending
myovantex102-myovantpfizer.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
myov-20221231_cal.xml Edgar Link unprocessable
myov-20221231_def.xml Edgar Link unprocessable
myov-20221231_lab.xml Edgar Link unprocessable
myov-20221231_pre.xml Edgar Link unprocessable
myov-20221231_htm.xml Edgar Link completed
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable